Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus [Cost-effectiveness of universal rotavirus vaccination with Rix4414 in Italy]

Objectives: Rotavirus (RV) is the most common etiological agent of gastroenteritis in children. The oral vaccine Rix4414 was recently commercialized in Italy for prevention of RV infections. The health outcomes and the economic impact of a national RV immunization program were assessed. Design: A Markov model simulated the flow of a birth cohort on RV disease burden and costs up to age 5, comparing a RV vaccination programme with no vaccination. Lifetime cost-effectiveness for the national healthcare system (NHS) and the society (S) with a benchmark of 50,000 €/QALY was analysed. Main results: Disease’s medical direct costs exceeded 30 million €/year, while indirect costs approached 112 mil…

A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy

Vaccination of all healthy children against rotavirus (RV) has been recommended, since the availability of vaccines, both in Europe (PIDJ) and Italy (pediatricians). The aims of universal vaccination against RV include the protection of children against moderate/severe gastroenteritis forms by RV (GARV), prevent hospitalizations, reduce the severity and duration of the disease, and reduce morbidity and socioeconomic costs. Payers need to informed regarding the efficacy and the healthcare utilization related to RV vaccination in order to decide in favour of its extensive implementation. The aim of this paper is to assess the clinical and financial impact of the extensive vaccination aganist …

I database regionali ICD9-CM costituiscono uno strumento utile ed efficace per stimare i ricoveri ospedalieri prima e dopo l'introduzione della vaccinazione anti-rotavirus in Italia